Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3089 - Prognostic factors in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) or bicalutamide (BIC) in TERRAIN


09 Oct 2016


Poster display


Axel Heidenreich


Annals of Oncology (2016) 27 (6): 243-265. 10.1093/annonc/mdw372


A. Heidenreich1, N. Shore2, A. Villers3, L. Klotz4, D.R. Siemens5, S. van Os6, B. Baron7, F. Wang8, S. Chowdhury9

Author affiliations

  • 1 Urology, Cologne University, 50937 - Cologne/DE
  • 2 Urology, Carolina Urologic Research Center, Myrtle Beach/US
  • 3 Urology, Lille University, Lille/FR
  • 4 Urology, Sunnybrook Health Sciences Centre, M4N 3M5 - Toronto/CA
  • 5 Urology, Centre for Applied Urological Research, Queen’s University, Kingston/CA
  • 6 Global Development Oncology, Astellas Pharma, Inc., Leiden/NL
  • 7 Data Science, Astellas Pharma, Inc., Leiden/NL
  • 8 Clinical Development, Medivation, Inc., San Francisco/US
  • 9 Medical Oncology, Guy’s, King’s and St. Thomas’ Hospitals, London/GB


Abstract 3089


In TERRAIN, men with mCRPC who had progressed during luteinising hormone receptor hormone agonist/antagonist (LHRHa) treatment or after bilateral orchiectomy were randomised to ENZA or BIC. This post hoc analysis explores pre-treatment factors associated with progression-free survival (PFS) and time to prostate serum antigen (PSA) progression (TTP) and a risk group classification model based on the statistically and clinically predictive value of these factors.


Data from randomised men in TERRAIN were analysed. Cox regression analysis was used to identify pre-treatment factors associated with PFS and TTP as single or multiple variables in the model and to determine a risk group classification. PSA, testosterone, lactate dehydrogenase (LDH), alkaline phosphatase (ALP), albumin (ALB), haemoglobin, neutrophil-lymphocyte ratio (NLR), LHRHa/orchiectomy start date relative to diagnosis of metastasis, ECOG performance status, Gleason score, disease location and prior anti-androgen use were used as continuous or categorical variables. Models were stratified by study treatment.


Data from 375 men were analysed. PSA, LDH, ALP, ALB and disease location were prognostic factors for PFS and/or TTP in single and multiple variable models. NLR, haemoglobin and LHRHa start were prognostic factors in single variable models. For PFS and TTP, an efficient risk group classification with three prognostic risk groups was derived based on ALP, PSA and ALB (table). Median PFS for the best risk group (0–1) was 16.6 months vs 3.3 months for the worst risk group (4) [hazard ratio, 5.7; 95% confidence interval 4.0, 8.2].

Baseline parameter Total score Risk group


Three baseline laboratory parameters defined risk groups in a classification system and explained differential clinical benefits for men in TERRAIN, including the ENZA-treated subgroup.

Legal entity responsible for the study

Astellas Pharma, Inc. and Medivation, Inc.


Astellas Pharma, Inc. and Medivation, Inc.


A. Heidenreich: Advisory board member: Astellas, Bayer, Dendreon, Jansen, Sanofi. Corporate-sponsored research: Astellas, Bayer.

N. Shore: Advisory board member: Astellas, Bayer, Dendreon, Ferring, Janssen, Sanofi, Takeda.

A. Villers: Advisory board member: Astellas (2015).

L. Klotz: Advisory board member: Astellas, Medivation, Janssen, Amgen, Genomic Health, Abbvie, Ferring.

D.R. Siemens: Study investigator: Astellas

S. van Os: Employee of Astellas.

B. Baron: Employee of Astellas

F. Wang: Employee of Medivation. Owns Medivation stock.

S. Chowdhury: Advisory board member: Sanofi, Astellas, Novartis, Janssen, Bayer, Essa, Pfizer and Clovis. Corporate - sponsored research: Sanofi and Astellas.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.